PDCD1 and small cell lung carcinoma: As a result, to the best of our knowledge, this is currently the most comprehensive NMA evaluating the efficacy and safety of PD‐1 inhibitors plus chemotherapy versus PD‐L1 inhibitors plus chemotherapy in the first‐line treatment of ES‐SCLC.